NANO-X IMAGING LTD (www.nanox.vision) (“Nanox” or the “Company”), an innovative medical imaging technology company, announces it has secured over $100M in crossover equity investments from global investors since December 2019. Funds raised are planned to primarily support the rollout of the Nanox.ARC deployments worldwide.
Israeli-based A-Labs Advisory and Finance Ltd. was the lead advisor to the financing round.
The financing round was initiated in November 2019 and was delayed in closing due to the COVID-19 pandemic. Since November 2019, Nanox has signed agreements for the deployment of thousands of units of the Nanox System, its innovative medical imaging system and diagnostics services in eleven global regions. The Company aims to revolutionize early-detection healthcare by deploying a global medical imaging infrastructure at an affordable price-per-scan service model to maximize availability and accessibility of medical imaging to all socio-economic communities.
“It is easy to say that we are aiming to change the world,” says Ran Poliakine, Founder and Chief Executive Officer of Nanox. “The main challenge with such statements is always the execution. We have a bold vision to increase early detection of medical conditions that are discoverable by X-ray. We are actively working to deploy a global medical imaging service infrastructure that may turn this dream into reality. We cannot do it without partners and investors who share our vision and support our plan. I thank our investors at SK Telecom, Foxconn, Industrial Alliance and Yozma Korea for their faith and trust in the Nanox team and vision.”
“The innovative approach of preventive healthcare and the MEMs X-ray source have driven us, The Yozma Group Asia, to invest in Nanox. Potentially reduced radiation exposure and lowered cost can set a new standard of regular health checkups,” says Wonjae Lee, Head of Asia Pacific and Managing Partner of Yozma Group. “I’m honored to be a part of the Nanox project not only because its technology is groundbreaking and contributing to mankind, but also because it’s the best example of multinational collaboration. As a strategic investor, The Yozma Group Asia is eager to make a global success case of Asian and Israeli collaboration by merging Nanox innovative technology and Korea’s outstanding manufacturing knowhow.”
Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, please visit www.nanox.vision.
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox’s research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.Arc. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises could cause a disruption of the development, deployment or regulatory clearance of the Nanox System and adversely impact our business; Nanox’s ability to develop and produce a working prototype of the Nanox.Arc; Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.Arc from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; the market acceptance of the Nanox.Arc and the proposed pay-per-scan business model; Nanox’s expectations regarding collaborations with third-parties and their potential benefits; and Nanox’s ability to conduct business globally, among others. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox’s expectations.